Semper Paratus furnishes investor presentation for proposed Tevogen Bio merger

Tevogen Bio Holdings Inc.

Presentation provides additional detail on June 28, 2023 merger agreement between SPAC and Tevogen Bio.
Transaction involves exchange of all Tevogen Bio capital stock for Semper Paratus Class A shares.
Closing conditions include shareholder approval, regulatory clearances, and minimum cash requirements.
No new financial projections or material updates disclosed in this filing beyond the presentation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.